Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
about
Role of bile acids in the regulation of the metabolic pathwaysBile acid receptors and nonalcoholic fatty liver diseaseHepatic farnesoid X-receptor isoforms α2 and α4 differentially modulate bile salt and lipoprotein metabolism in miceCrosstalk of HNF4α with extracellular and intracellular signaling pathways in the regulation of hepatic metabolism of drugs and lipidsBile acid nuclear receptor FXR and digestive system diseasesBile acid signaling in metabolic disease and drug therapyFarnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulationFarnesoid X receptor is essential for normal glucose homeostasisCoordinated Actions of FXR and LXR in Metabolism: From Pathogenesis to Pharmacological Targets for Type 2 DiabetesBile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration.Bile acid sequestrants for lipid and glucose control.Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR/RXR-dependent and independent mechanisms.Genome-wide interrogation of hepatic FXR reveals an asymmetric IR-1 motif and synergy with LRH-1.Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance.Tissue specific induction of p62/Sqstm1 by farnesoid X receptor.Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics.Deciphering the nuclear bile acid receptor FXR paradigm.Nonalcoholic fatty liver disease: molecular pathways and therapeutic strategiesNutrient-sensing nuclear receptors coordinate autophagy.Tissue-specific function of farnesoid X receptor in liver and intestineFarnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity.Saponins of Panax notoginseng: chemistry, cellular targets and therapeutic opportunities in cardiovascular diseases.Farnesoid X receptor represses hepatic human APOA gene expression.Bile Acid signaling in liver metabolism and diseases.Effects of FXR in foam-cell formation and atherosclerosis development.Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity.Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease.Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids.Thyroid hormone reduces cholesterol via a non-LDL receptor-mediated pathway.FXR: a target for cholestatic syndromes?Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR.Pharmacology of bile acid receptors: Evolution of bile acids from simple detergents to complex signaling molecules.Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic micePrescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.Lithocholic acid decreases expression of UGT2B7 in Caco-2 cells: a potential role for a negative farnesoid X receptor response element.The farnesoid X receptor regulates transcription of 3beta-hydroxysteroid dehydrogenase type 2 in human adrenal cells.Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR-/- and apoE-/- miceEndocrine and paracrine role of bile acidsThe role of FXR in disorders of bile acid homeostasis.FXR an emerging therapeutic target for the treatment of atherosclerosis
P2860
Q26738976-8AF11077-80C0-4CBF-9C1E-12AF7BAE7356Q26775814-8E91C765-B8E8-41CE-ADAE-707489DC1CB5Q27320737-346A255F-49DD-45C9-A00D-F959EA521487Q28080239-1EB50A20-EFDC-430F-9260-63D2E0ED7E52Q28085493-D1126B08-DFE2-459A-AE8C-D1CE3D75977DQ28244875-09B46A68-997E-431E-B6B5-FDDCFE5D30FAQ28581627-D6991412-4BC1-4A31-8343-E35FD4C53763Q28591952-BE08ECE9-D5AD-447E-ABFF-D6B5B1D0BEA9Q33608251-A89095D4-573C-4D26-9171-124E757FE0D4Q33610738-07C2306A-0092-409D-8646-A0A8AF0DB91AQ33651272-19BF7E9E-9BE1-495B-9027-56E3E32D2041Q33993174-20712DEA-35D9-4C9F-A82A-8B1D9B63BD6CQ34189248-BC7AA7AE-7CD7-42B5-8C69-20730D8DC827Q34325594-41B69DD6-E502-4C46-AA0B-5BBA071E1461Q34405939-5D24B249-817D-44E8-BBA7-B328AE0DBB36Q34480492-72162A7A-7A48-43E6-8122-EBBC7D229664Q34626518-18B0FF84-AEDD-45DB-8EEF-B4BBEF6D8BAEQ34657286-F4A7EBC6-0FCE-4BF8-8B0A-E2F511165D33Q34713459-7673E87D-C37C-41E9-AB3A-A716575B7637Q34714107-E9CE5F01-5D5F-4A21-82E7-BFE6896EB362Q35063271-C4D144B6-D8CA-4041-96FA-F56778F6B86EQ35099028-6FF416B4-3C81-4105-A785-5A1F07094C0FQ35187047-74F84D26-679F-49AB-813C-F4F2C9BD8D17Q35257218-719F19C9-7A0C-42CA-82CA-440D989314F0Q35546179-0FE569D4-0177-4CD5-9337-C66A9DB7DFABQ35672242-DBA54AC9-1FA4-4FE5-90D6-34052CFD3964Q36145170-0CC334BB-AF63-45D9-AE20-3AC367A2C905Q36237911-5F1B2A44-D959-4EFE-A897-C3F36B8A59B0Q36323148-40E1751F-3652-47C2-B159-B2603E115F01Q36481061-A01351A8-7294-4EAA-B954-EF929128BE13Q36683297-E19B364B-D64D-4FBD-956C-370F38250807Q36987335-2A82EAF7-B916-478A-9DEB-3D856F7D1395Q37002680-013A6994-56C5-4B23-83E7-9542220F9C69Q37104877-F78824E6-7845-4092-9F82-F15D3C0F42F5Q37120614-FC3EDADA-0640-41BA-AD71-6DEECA7E444CQ37184702-7015DDE2-6E63-4D8F-AE0C-8642D98C9023Q37190365-F0EBDB7E-E3BC-49DA-86A8-6F775AFC1970Q37287593-7886DBD9-E07F-4E29-A809-436D9B60F1CAQ37300843-D168715B-6908-4B1C-8D0C-02DE33174DC3Q37334984-E62433EB-689A-40F7-A5A5-C58AF0BC2E81
P2860
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
description
2003 nî lūn-bûn
@nan
2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
@ast
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
@en
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
@nl
type
label
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
@ast
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
@en
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
@nl
prefLabel
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
@ast
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
@en
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
@nl
P2093
P3181
P1433
P1476
Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
@en
P2093
Daniel Duran-Sandoval
Frank J Gonzalez
Jamila Fruchart
Olivier Barbier
Thierry Claudel
Vladimir Kosykh
Yusuke Inoue
P304
P3181
P356
10.1016/S0016-5085(03)00896-5
P407
P577
2003-08-01T00:00:00Z